Minerva - where you at the back of the room or in the middle on my right ?
I must admit - the CR suggestion would be odd given RP statements that they can utilise their cash extra projects
In addition the suggestion we would be wiped out with a CR is a bit extreme also , if it broadened the pipeline with clinical stage opportunities I think it would be a positive
Lastly as Australian shareholders , the falling AUD is not on helping improve a AUD share price but also will mean significant returns for us in AUD terms from USD revenue
Add to My Watchlist
What is My Watchlist?